Who Paid My Doc
Peter Lucas
Molecular Genetic Pathology Rochester, MN Medical Doctor
NPI 1457433419 CMS profile 689944
200 1St St Sw, Spc 5002, Rochester, MN 55905
General payments
$0
Research payments
$3,432
Ownership & investment interest
$0
Through program year 2023, Peter Lucas of Rochester, MN is reported in the CMS Open Payments database as having received $0 across 0 general payments and $3,432 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2023 | Research | $3,432 | 3 |
Records
3 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Molecular Genetic Pathology in Minnesota
Related records
Molecular Genetic Pathology in Minnesota
Practitioners in the same specialty and state, ranked by reported value.
All Molecular Genetic Pathology
Everyone recorded under this specialty, nationwide.
Doctors in Minnesota
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.